JP2022508155A5 - - Google Patents
Info
- Publication number
- JP2022508155A5 JP2022508155A5 JP2021528339A JP2021528339A JP2022508155A5 JP 2022508155 A5 JP2022508155 A5 JP 2022508155A5 JP 2021528339 A JP2021528339 A JP 2021528339A JP 2021528339 A JP2021528339 A JP 2021528339A JP 2022508155 A5 JP2022508155 A5 JP 2022508155A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition according
- inhibitor
- agent
- melanoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862770446P | 2018-11-21 | 2018-11-21 | |
| US62/770,446 | 2018-11-21 | ||
| US201962798238P | 2019-01-29 | 2019-01-29 | |
| US62/798,238 | 2019-01-29 | ||
| US201962858036P | 2019-06-06 | 2019-06-06 | |
| US62/858,036 | 2019-06-06 | ||
| PCT/US2019/062525 WO2020106915A1 (en) | 2018-11-21 | 2019-11-21 | Methods of treating cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022508155A JP2022508155A (ja) | 2022-01-19 |
| JP2022508155A5 true JP2022508155A5 (enExample) | 2022-11-29 |
Family
ID=70774067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021528339A Pending JP2022508155A (ja) | 2018-11-21 | 2019-11-21 | がんを治療する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20220016083A1 (enExample) |
| EP (1) | EP3883580A4 (enExample) |
| JP (1) | JP2022508155A (enExample) |
| CN (1) | CN113573734A (enExample) |
| WO (1) | WO2020106915A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12282014B2 (en) | 2015-11-19 | 2025-04-22 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers |
| EP3746124A4 (en) | 2018-01-30 | 2021-10-27 | Foghorn Therapeutics Inc. | COMPOUNDS AND THEIR USES |
| US12473334B2 (en) | 2018-10-17 | 2025-11-18 | Dana-Farber Cancer Institute, Inc. | SWI/SNF family chromatin remodeling complexes and uses thereof |
| AU2020214308A1 (en) * | 2019-01-29 | 2021-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12509453B2 (en) | 2019-01-29 | 2025-12-30 | Foghorn Therapeutics Inc. | BRM/BRG1 inhibitors and uses thereof |
| EP3917517A4 (en) | 2019-01-29 | 2023-01-25 | Foghorn Therapeutics Inc. | CONNECTIONS AND USES THEREOF |
| BR112022015109A2 (pt) * | 2020-01-29 | 2022-11-08 | Foghorn Therapeutics Inc | Compostos e usos dos mesmos |
| WO2021155264A1 (en) | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2021155262A1 (en) * | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| CN119823124A (zh) | 2020-03-05 | 2025-04-15 | C4医药公司 | 用于brd9的靶向降解的化合物 |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| US20230295735A1 (en) * | 2020-06-18 | 2023-09-21 | Epizyme, Inc. | Smarca4 inhibition for the treatment of cancer |
| KR20230128471A (ko) * | 2020-12-04 | 2023-09-05 | 에우불루스 바이오테라퓨틱스 인코포레이티드 | 헤테로아릴-아세틸렌, 이의 약제학적 조성물, 및 이의치료적 적용 |
| US12606553B2 (en) | 2021-03-09 | 2026-04-21 | Foghorn Therapeutics Inc. | Crystalline forms, compositions containing same, and methods of their use |
| US20240374605A1 (en) * | 2021-07-29 | 2024-11-14 | Foghorn Therapeutics Inc. | Methods of treating cancer |
| US20230265432A1 (en) * | 2021-10-21 | 2023-08-24 | Sanford Burnham Prebys Medical Discovery Institute | Methods and compositions for treating acute myeloid leukemia |
| WO2023234954A1 (en) * | 2022-06-03 | 2023-12-07 | Immunocore Limited | Methods of treating melanoma using tebentafusp and immune checkpoint inhibitors |
| AU2023343029A1 (en) | 2022-09-13 | 2025-03-27 | Amphista Therapeutics Limited | Compounds for targeted protein degradation |
| WO2024086577A1 (en) * | 2022-10-17 | 2024-04-25 | Foghorn Therapeutics Inc. | Methods of reducing or preventing metastases |
| WO2026052822A1 (en) | 2024-09-06 | 2026-03-12 | Amphista Therapeutics Limited | Tetrahydroisoquinoline compounds for targeted protein degradation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2900301T3 (es) * | 2013-03-15 | 2022-03-16 | Novartis Ag | Biomarcadores asociados con la inhibición de BRM |
| US20160130663A1 (en) * | 2013-07-12 | 2016-05-12 | National Cancer Center | Method for predicting response to cancer treatment |
| US9694084B2 (en) * | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| MA41598A (fr) * | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| CA2994969A1 (en) * | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
| US12023385B2 (en) * | 2017-02-08 | 2024-07-02 | Dana-Farber Cancer Institute, Inc. | Tunable endogenous protein degradation with heterobifunctional compounds |
| KR20190140438A (ko) * | 2017-02-28 | 2019-12-19 | 에피자임, 인코포레이티드 | 암 치료를 위한 smarca2의 저해 |
-
2019
- 2019-11-21 EP EP19887386.1A patent/EP3883580A4/en not_active Withdrawn
- 2019-11-21 CN CN201980089704.1A patent/CN113573734A/zh active Pending
- 2019-11-21 US US17/295,327 patent/US20220016083A1/en not_active Abandoned
- 2019-11-21 JP JP2021528339A patent/JP2022508155A/ja active Pending
- 2019-11-21 WO PCT/US2019/062525 patent/WO2020106915A1/en not_active Ceased
-
2025
- 2025-02-19 US US19/057,594 patent/US20250235432A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022543555A5 (enExample) | ||
| US20200000787A1 (en) | Medicament for treatment of liver cancer | |
| WO2021243280A2 (en) | Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9 | |
| US10441587B2 (en) | Treatment of lung cancer with inhibitors of glutaminase | |
| HRP20210848T1 (hr) | Sastavi i postupci za sprječavanje aktivnosti arginaze | |
| CN1315479C (zh) | 橄榄苦苷在制备抑制血管生成药物中的用途 | |
| JP2017517548A (ja) | グルタミナーゼ阻害剤との併用療法 | |
| RU2014115847A (ru) | Пирролопиримидиновые соединения для лечения злокачественной опухоли | |
| JP2008528671A5 (enExample) | ||
| JP2017528475A5 (enExample) | ||
| TW201002312A (en) | Induction of tumor hypoxia for cancer therapy | |
| Kerbel | Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs | |
| JP2024530956A5 (enExample) | ||
| JP2005508857A (ja) | 新生物疾患処置用の薬剤組み合わせ | |
| WO2018039442A1 (en) | Treatment of cancer with inhibitors of glutaminase | |
| JP2018501261A5 (enExample) | ||
| TW202502354A (zh) | 同源重組修復缺陷（ｈｒｄ）作為預測性生物標記以便使用ｗｅｅ１抑制劑治療癌症 | |
| US20150065526A1 (en) | Overcoming acquired resistance to chemotherapy treatments through suppression of stat3 | |
| Taketo | Roles of stromal microenvironment in colon cancer progression | |
| CN117959315B (zh) | 化合物pgg作为krasg12d抑制剂mrt1133的增效剂联合治疗胰腺癌的应用 | |
| WO2009047216A2 (en) | Use of indolocarbazole imides as protein kinase inhibitors for the treatment of hematologic and solid tumors | |
| CN106714795A (zh) | 用于治疗尤因家族肿瘤的组合物及方法 | |
| FR2968557A1 (fr) | Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab | |
| JP2019532937A (ja) | Ｒｎａポリメラーゼｉ阻害に基づく、がんの併用治療戦略 | |
| JP2008533161A5 (enExample) |